Results 111 to 120 of about 18,425 (234)
Planning and evaluation of bioequivalence studies of rosuvastatin drug products
The article reviews bioequivalence studies of Russian and foreign generic rosuvastatin preparations with the goal of harmonizing approaches to rosuvastatin bioequivalence studies in the Russian Federation.
D. P. Romodanovsky, D. V. Goryachev
doaj
As the field of personalized dosing develops, the pharmaceutical manufacturing industry needs to offer flexibility in terms of tailoring the drug release and strength to the individual patient’s needs.
Olha Shuklinova +7 more
doaj +1 more source
Raymond R Tjandrawinata,1 Effi Setiawati,2 Danang Agung Yunaidi,2 Iwan Dwi Santoso,2 Arini Setiawati,3 Liana W Susanto11Dexa Laboratories of Biomolecular Sciences (DLBS), Cikarang, Indonesia; 2Bioavailability and Bioequivalence Laboratory, Equilab ...
Tjandrawinata RR +5 more
core
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Comparative bioequivalence studies of tramadol hydrochloride sustained-release 200 mg tablets
Suhas S Khandave1, Satish V Sawant1, Santosh S Joshi1, Yatish K Bansal2, Sonal S Kadam21Accutest Research Laboratories (I) Private Limited, Koparkhirne, Navi Mumbai, Maharashtra, India; 2Ipca Laboratories Limited, Kandivli Mumbai, Maharashtra ...
Khandave Suhas +8 more
core +1 more source
Highly variable medicines - specific aspects of bioequivalence studies
At present a specific group of medicines - highly variable medicines - is distinguished based on intraindividual variability data (CVintra > 30%). It is quite difficult to confirm therapeutic equivalence of highly variable medicines by pharmacokinetic ...
D. P. Romodanovsky +6 more
doaj
Bioequivalence Study of Two Formulations Containing Rosuvastatin 40 Mg Tablets in Healthy Colombians
4 páginasThis is a pharmacokinetic study of two formulations containing Rosuvastatin 40 mg, with the aim to compare the Bioavailability between the Test product (Rosuvastatin made by Laboratorios Tecnoquímicas S.A., Colombia) and the Reference product ...
Bustamante C., Vargas M., Villarraga E.
core +1 more source
Background: Denecimig (Mim8, Novo Nordisk A/S) is a next-generation bispecific antibody designed to mimic activated factor (F)VIII and restore hemostasis in persons with hemophilia A.
Jacob Lund +3 more
doaj +1 more source
Generic drug product development : bioequivalence issues /
Includes bibliographical references and index.Bioequivalence using clinical endpoint studies / Christopher Hendy -- Evaluation of bioequivalence of highly variable drugs / Laszlo Endrenyi and Laszlo Tothfalusi -- Statistical considerations: alternate ...
Shargel, Leon(viaf)111014464 +1 more
core

